Chemical compound
BR: Class F2 (Prohibited psychotropics)
CA: Schedule II
DE: Anlage II (Authorized trade only, not prescriptible)
UK: Class B
US: Schedule I
IUPAC name
Methyl (S)-2--3,3-dimethylbutanoate
1715016-75-3
101895417
32741709
FD7BD1M9FYUN52BPP7RB(racemate)
DTXSID201009974 
100.257.468
C20H28FN3O3
377.460 g·mol−1
Interactive image
SMILES
FCCCCC2C1=CC=CC=C1C(=N2)C(=O)N(C(=O)OC)C(C)(C)C
InChI
InChI=1S/C20H28FN3O3/c1-20(2,3)17(19(26)27-4)22-18(25)16-14-10-6-7-11-15(14)24(23-16)13-9-5-8-12-21/h6-7,10-11,17H,5,8-9,12-13H2,1-4H3,(H,22,25)/t17-/m1/s1Key:PWEKNGSNNAKWBL-QGZVFWFLSA-N
5F-ADB (also known as 5F-MDMB-PINACA) is an indazole-based synthetic cannabinoid from the indazole-3-carboxamide family, which has been used as an active ingredient in synthetic cannabis products and has been sold online as a designer drug. 5F-ADB is a potent agonist of the CB1 receptor, though it is unclear whether it is selective for this target. 5F-ADB was first identified in November 2014 from post-mortem samples taken from an individual who had died after using a product containing this substance. Subsequent testing identified 5F-ADB to have been present in a total of ten people who had died from unexplained drug overdoses in Japan between September 2014 and December 2014. 5F-ADB is believed to be extremely potent based on the very low levels detected in tissue samples, and appears to be significantly more toxic than earlier synthetic cannabinoid drugs that had previously been sold.
In 2018, 5F-ADB was the most common synthetic cannabinoid to be identified in Drug Enforcement Administration seizures. 5F-ADB was also identified in cannabidiol (CBD) products from a US-based CBD manufacturer in 2018.
Deaths
5F-MDMB-PINACA has been associated with 25 deaths in Europe between 2015 and 2017.
Legal status
In the United States, 5F-ADB is a schedule I controlled substance.
5F-ADB was added to the Japanese banned drug list in December 2014.
